# Dyne Therapeutics, Inc.: financial statements, quarterly

DYN · Nasdaq · CIK 1818794 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dyn.md) · [Financials](/companies/dyn/financials.md) · [Filings](/companies/dyn/filings.md) · [Insiders](/companies/dyn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dyn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [55.3](/filings/0000950170-24-124572.md) | [58.8 d](/filings/0001193125-26-084178.md) | [44.5](/filings/0000950170-25-066386.md) | [62.3](/filings/0000950170-25-099161.md) | [92.8](/filings/0001193125-25-266882.md) | [81.8 d](/filings/0001193125-26-084178.md) | [106](/filings/0001193125-26-215702.md) | [99.2](/filings/0001193125-26-323639.md) | [97.2](/filings/0001193125-25-266882.md) | [95.4 d](/filings/0001193125-26-084178.md) | [101](/filings/0001193125-26-215702.md) | [152](/filings/0001193125-26-323639.md) |
| Operating income | $m | [(62.3)](/filings/0000950170-24-124572.md) | [(67.7) d](/filings/0001193125-26-084178.md) | [(69.2)](/filings/0000950170-25-066386.md) | [(72.0)](/filings/0000950170-25-099161.md) | [(106)](/filings/0001193125-25-266882.md) | [(97.1) d](/filings/0001193125-26-084178.md) | [(122)](/filings/0001193125-26-215702.md) | [(116)](/filings/0001193125-26-323639.md) | [(114)](/filings/0001193125-25-266882.md) | [(116) d](/filings/0001193125-26-084178.md) | [(125)](/filings/0001193125-26-215702.md) | [(182)](/filings/0001193125-26-323639.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-25-266882.md) | not reported | not reported | [0.1](/filings/0000950170-25-099161.md) | [2.9](/filings/0001193125-25-266882.md) | not reported | not reported | not reported |
| Net income | $m | [(60.2)](/filings/0000950170-24-124572.md) | [(66.6) d](/filings/0001193125-26-084178.md) | [(65.6)](/filings/0001193125-25-266882.md) | [(65.1)](/filings/0001193125-25-266882.md) | [(97.1)](/filings/0001193125-25-266882.md) | [(89.5) d](/filings/0001193125-26-084178.md) | [(115)](/filings/0001193125-26-323639.md) | [(111)](/filings/0001193125-26-323639.md) | [(108)](/filings/0001193125-25-266882.md) | [(112) d](/filings/0001193125-26-084178.md) | [(121)](/filings/0001193125-26-323639.md) | [(179)](/filings/0001193125-26-323639.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0000950170-24-124572.md) | not reported | [(0.81)](/filings/0000950170-25-066386.md) | [(0.70)](/filings/0000950170-25-099161.md) | [(0.96)](/filings/0001193125-25-266882.md) | not reported | [(1.05)](/filings/0001193125-26-215702.md) | [(0.97)](/filings/0001193125-26-323639.md) | [(0.76)](/filings/0001193125-25-266882.md) | not reported | [(0.73)](/filings/0001193125-26-215702.md) | [(1.08)](/filings/0001193125-26-323639.md) |
| Basic EPS | $ per share | [(0.99)](/filings/0000950170-24-124572.md) | not reported | [(0.81)](/filings/0000950170-25-066386.md) | [(0.70)](/filings/0000950170-25-099161.md) | [(0.96)](/filings/0001193125-25-266882.md) | not reported | [(1.05)](/filings/0001193125-26-215702.md) | [(0.97)](/filings/0001193125-26-323639.md) | [(0.76)](/filings/0001193125-25-266882.md) | not reported | [(0.73)](/filings/0001193125-26-215702.md) | [(1.08)](/filings/0001193125-26-323639.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [130](/filings/0000950170-23-056121.md) | [122](/filings/0000950170-25-028356.md) | [272](/filings/0000950170-24-052066.md) | [608](/filings/0000950170-24-095527.md) | [532](/filings/0000950170-24-124572.md) | [435](/filings/0001193125-26-084178.md) | [472](/filings/0000950170-25-066386.md) | [485](/filings/0000950170-25-099161.md) | [574](/filings/0001193125-25-266882.md) | [893](/filings/0001193125-26-323639.md) | [753](/filings/0001193125-26-215702.md) | [676](/filings/0001193125-26-323639.md) |
| Current assets | $m | [168](/filings/0000950170-23-056121.md) | [129](/filings/0000950170-25-028356.md) | [488](/filings/0000950170-24-052066.md) | [792](/filings/0000950170-24-095527.md) | [736](/filings/0000950170-24-124572.md) | [659](/filings/0001193125-26-084178.md) | [690](/filings/0000950170-25-066386.md) | [698](/filings/0000950170-25-099161.md) | [806](/filings/0001193125-25-266882.md) | [1,127](/filings/0001193125-26-323639.md) | [1,021](/filings/0001193125-26-215702.md) | [938](/filings/0001193125-26-323639.md) |
| Total assets | $m | [205](/filings/0000950170-23-056121.md) | [165](/filings/0000950170-25-028356.md) | [522](/filings/0000950170-24-052066.md) | [826](/filings/0000950170-24-095527.md) | [769](/filings/0000950170-24-124572.md) | [691](/filings/0001193125-26-084178.md) | [721](/filings/0000950170-25-066386.md) | [729](/filings/0000950170-25-099161.md) | [867](/filings/0001193125-25-266882.md) | [1,187](/filings/0001193125-26-323639.md) | [1,080](/filings/0001193125-26-215702.md) | [994](/filings/0001193125-26-323639.md) |
| Current liabilities | $m | [29.7](/filings/0000950170-23-056121.md) | [51.1](/filings/0000950170-25-028356.md) | [22.4](/filings/0000950170-24-052066.md) | [29.8](/filings/0000950170-24-095527.md) | [43.3](/filings/0000950170-24-124572.md) | [42.3](/filings/0001193125-26-084178.md) | [33.9](/filings/0000950170-25-066386.md) | [41.5](/filings/0000950170-25-099161.md) | [59.8](/filings/0001193125-25-266882.md) | [50.6](/filings/0001193125-26-323639.md) | [51.2](/filings/0001193125-26-215702.md) | [78.0](/filings/0001193125-26-323639.md) |
| Total liabilities | $m | [53.2](/filings/0000950170-23-056121.md) | [73.8](/filings/0000950170-25-028356.md) | [44.2](/filings/0000950170-24-052066.md) | [50.7](/filings/0000950170-24-095527.md) | [63.3](/filings/0000950170-24-124572.md) | [61.4](/filings/0001193125-26-084178.md) | [52.1](/filings/0000950170-25-066386.md) | [158](/filings/0000950170-25-099161.md) | [175](/filings/0001193125-25-266882.md) | [215](/filings/0001193125-26-323639.md) | [215](/filings/0001193125-26-215702.md) | [292](/filings/0001193125-26-323639.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-084178.md) | not reported | [98.8](/filings/0000950170-25-099161.md) | [99.1](/filings/0001193125-25-266882.md) | [149](/filings/0001193125-26-323639.md) | [149](/filings/0001193125-26-215702.md) | [199](/filings/0001193125-26-323639.md) |
| Shareholders' equity | $m | [152](/filings/0000950170-24-124572.md) | [91.3](/filings/0001193125-26-084178.md) | [478](/filings/0001193125-25-266882.md) | [775](/filings/0001193125-25-266882.md) | [706](/filings/0001193125-25-266882.md) | [630](/filings/0001193125-26-323639.md) | [669](/filings/0001193125-26-323639.md) | [571](/filings/0001193125-26-323639.md) | [692](/filings/0001193125-25-266882.md) | [972](/filings/0001193125-26-323639.md) | [865](/filings/0001193125-26-323639.md) | [702](/filings/0001193125-26-323639.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(50.6) d](/filings/0000950170-24-124572.md) | [(35.0) d](/filings/0001193125-26-084178.md) | [(78.5)](/filings/0000950170-25-066386.md) | [(54.9) d](/filings/0000950170-25-099161.md) | [(74.6) d](/filings/0001193125-25-266882.md) | [(84.3) d](/filings/0001193125-26-084178.md) | [(106)](/filings/0001193125-26-215702.md) | [(94.7) d](/filings/0001193125-26-323639.md) | [(90.8) d](/filings/0001193125-25-266882.md) | [(112) d](/filings/0001193125-26-084178.md) | [(145)](/filings/0001193125-26-215702.md) | [(130) d](/filings/0001193125-26-323639.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-124572.md) | [0.1 d](/filings/0001193125-26-084178.md) | [0.2](/filings/0000950170-25-066386.md) | [0.9 d](/filings/0000950170-25-099161.md) | [0.3 d](/filings/0001193125-25-266882.md) | [1.1 d](/filings/0001193125-26-084178.md) | [1.0](/filings/0001193125-26-215702.md) | [0.1 d](/filings/0001193125-26-323639.md) | [0.4 d](/filings/0001193125-25-266882.md) | [0.5 d](/filings/0001193125-26-084178.md) | [0.2](/filings/0001193125-26-215702.md) | [1.5 d](/filings/0001193125-26-323639.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

Shares outstanding: 186,746,431 at 2026-07-24, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-323639.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.